Sun Pharmaceutical
If Nifty trades above 15,870, it may rally up to 16,150; ICICI Bank, SBI Life among 4 technical stocks to buy
The intraday chart suggests, traders may take a caution stance near the 15900/53200 level
Cipla share price hits record high on DCGI nod to import Moderna vaccine to treat COVID-19; may rally 12% more
Cipla share price hit a new record high of Rs 997.20 apiece in intraday on BSE on Wednesday, after the DCGI approved the firm to import Moderna, a Covid-19 vaccine, with emergency use authorisation in India.
No plans to get into vaccine production as it requires separate manufacturing infra: Sun Pharma
Commenting on the company's Halol plant, which has been under the USFDA radar for the last few years, Shanghvi said the drug firm is waiting for the regulator to inspect the facility.
Sun Pharma Q4 net profit zooms over twofold to Rs 894.15 crore
The company had posted a net profit of Rs 399.84 crore in the corresponding period of the previous fiscal, Sun Pharma said in a regulatory filing.
Nifty may hit 15,700, Sensex seen at 52,000 in 2021; Sanjiv Bhasin tells top stocks to buy | IIFL INTERVIEW
Sanjiv Bhasin, Director at IIFL Securities Ltd, said that investors must stay invested as BSE Sensex and Nifty 50 have been hitting record levels almost every other day
Sun Pharma share price jumps 4.2%; $400 million outgo turns out to be company’s gain
Pharmaceutical major Sun Pharma’s share price surged 4.2% on Friday morning despite the weaker sentiment in the domestic equity markets, which were down close to 1%.
Pharma earnings to reflect full COVID-19 impact in Apr-Jun quarter; 4 pharma stocks to gain up to 16%
Pharmaceutical sector will reflect the full impact of COVID-19 restrictions on the back of pre-buying in chronic therapies in March quarter, underperformance in the acute segment due to delays in elective surgeries and shut-d
Sun Pharma share price rallies 62% from March lows; should you buy the stock? Check target prices
Sun Pharmaceuticals Industries stock has been on a gaining spree since it touched a 52-week low of Rs 315.20 in March this year
Sun Pharma, Aurobindo Pharma among top stock picks from Pharma sector; CLSA sees gain up to 30%
Among pharma stocks, the top stock picks of CLSA are Sun Pharma, Cipla, Aurobindo Pharma and Cadila Healthcare, recommending a 'buy' rating on them
Strides Shasun gets CCI nod to buy Sun Pharma’s two divisions
The agreement involves transfer of these two marketing divisions along with employees to Strides for a consideration of Rs 165 crore Strides Shasun has received Competition Commission of India (CCI’s) approval to acquir
Strides Shasun gets CCI nod to buy Sun Pharma’s two divisions
In September last year, Sun Pharma and Strides signed an agreement related to erstwhile Ranbaxy's 'Solus' and 'Solus Care' divisions that are into central nervous system (CNS) segment in India.
Maintain ‘equalweight on Sun Pharma: Morgan Stanley
The FDA uploaded the Halol Warning Letter (WL) on its website, detailing various observations (i.e. cGMP deviations) cited during the Sep'14 inspection...
Hold rating on Sun Pharma; Halol warning could delay recovery
Post issuance of the warning letter, approvals from Halol will continue to be withheld, which will impact future launches from the facility
Sun Pharmaceutical raises Rs 1,000 cr via NCDs
Sun Pharma Laboratories Ltd, a wholly-owned subsidiary of the company, has raised, on private placement basis, Rs 1,000 crore by allotment of 10,000 unsecured redeemable non-convertible debentures of a face value of Rs 10,00,
Sun Pharma divests US manufacturing unit
Divests Bryan unit to Nostrum Laboratories Sun Pharmaceutical Industries announced that as a part of its manufacturing consolidation in the US, one of its wholly-owned subsidiaries has entered into an agreement with Nostrum L
Sun Pharma to sell US-based manufacturing unit to Nostrum Lab
Drug major Sun Pharma today said it has sold its manufacturing unit in Ohio to Nostrum Laboratories Inc for an undisclosed sum as part of the company's consolidation of manufacturing business in the US.
Maintain ‘neutral’ on Sun Pharma, target Rs 817: Nomura
Sun Pharma (SUNP) announced approval for gGleevec on December 4, 2015. SUNP will launch gGleevec on February 1, 2016 with 180-day exclusivity.
Sun Pharmaceutical’s tender offer for InSite ends; to directly acquire shares
Sun Pharmaceutical Industries today said its arm Thea Acquisition Corp plans to exercise a 'top up option' to purchase shares directly from eyecare firm InSite Vision to hold 90 per cent stake in the US-based company to compl
